Literature DB >> 21264473

Lamotrigine therapy for paroxysmal dysarthria caused by multiple sclerosis: a case report.

P Valentino, R Nisticò, D Pirritano, G Bilotti, F Del Giudice, M Sturniolo, A Quattrone.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21264473     DOI: 10.1007/s00415-011-5901-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  4 in total

1.  Paroxysmal dysarthria and ataxia in multiple sclerosis and corresponding magnetic resonance imaging findings.

Authors:  Yongmei Li; Chun Zeng; Tianyou Luo
Journal:  J Neurol       Date:  2010-09-18       Impact factor: 4.849

2.  Paroxysmal dysarthria and ataxia in a patient with Behçet's disease.

Authors:  F G Akman-Demir; M Eraksoy; I H Gürvit; G Saruhan-Direskeneli; O Aral
Journal:  J Neurol       Date:  1995-05       Impact factor: 4.849

3.  Midbrain lesions and paroxysmal dysarthria in multiple sclerosis.

Authors:  Y Blanco; Y Compta; F Graus; A Saiz
Journal:  Mult Scler       Date:  2008-06       Impact factor: 6.312

4.  Paroxysmal dysarthria and ataxia after midbrain infarction.

Authors:  M Matsui; H Tomimoto; K Sano; K Hashikawa; H Fukuyama; H Shibasaki
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

  4 in total
  4 in total

1.  Progress in multiple sclerosis research in the last year.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  J Neurol       Date:  2012-06-22       Impact factor: 4.849

2.  Harry Lee Parker and paroxysmal dysarthria and ataxia.

Authors:  James P Klaas; David B Burkholder; Wolfgang Singer; Christopher J Boes
Journal:  Neurology       Date:  2013-01-15       Impact factor: 9.910

3.  Isolated paroxysmal dysarthria caused by a single demyelinating midbrain lesion.

Authors:  Luca Codeluppi; Guido Bigliardi; Annalisa Chiari; Stefano Meletti
Journal:  BMJ Case Rep       Date:  2013-10-16

Review 4.  Cerebellar Dysfunction in Multiple Sclerosis.

Authors:  Alastair Wilkins
Journal:  Front Neurol       Date:  2017-06-28       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.